Nebivolol ameliorates asymmetric dimethylarginine-induced vascular response in rat aorta via β3 adrenoceptor-mediated mechanism

Clinical and Experimental Hypertension : CHE
Yan Wang, Xiushan Dong

Abstract

Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase (NOS) inhibitor, induces endothelial dysfunction. Nebivolol, a highly selective β1-adrenergic receptor (AR) blocker, is the only beta-blocker known to induce vascular production of nitric oxide. The present study was designed to evaluate the effect and mechanism of nebivolol on ADMA-induced vascular response in rat aorta in vitro. In vitro, the effects of nebivolol and ADMA on resting tone or contraction induced by phenylephrine (PE, 10(-6 )mol/L) and relaxation induced by acetylcholine (Ach, 10(-10)-10(-5 )mol/L) were evaluated. ADMA in a concentration-dependent manner increased the resting and PE-induced tone and reduced Ach-induced relaxation. Nebivolol inhibited the ADMA-induced enhancements in tone and reversed the effects of ADMA on Ach-induced relaxation. These effects of nebivolol were blocked by selective β3 receptor blocker cyanopindolol (1 μM), but not by selective β2 receptor blocker butoxamine (50 μM). Nebivolol ameliorates the ADMA-induced vascular responses in rat aorta, at least in part, by mechanisms involving β3 adrenoceptor.

References

Oct 8, 1999·Stroke; a Journal of Cerebral Circulation·G SegarraD A Pelligrino
Sep 5, 2001·Kidney International·S T MorrisA G Jardine
Jan 29, 2002·Journal of Cardiovascular Pharmacology·J M Ritter
Jan 29, 2002·Journal of Cardiovascular Pharmacology·T F LüscherF Cosentino
Sep 5, 2002·British Journal of Pharmacology·Yohann RautureauChantal Gauthier
Jul 29, 2003·Journal of Cardiovascular Pharmacology·Annemieke A de GrootStephan L M Peters
Feb 1, 2005·European Journal of Pharmacology·Adriana GeorgescuDoina Popov
Jul 20, 2006·Annual Review of Nutrition·Michiel P C SiroenPaul A M van Leeuwen
Feb 7, 2007·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Stefano EvangelistaLuciano Cominacini
Nov 13, 2007·Clinical and Experimental Hypertension : CHE·Jie LiYuan-Jian Li
Mar 31, 2009·Journal of Hypertension·Uta HillebrandMartin Hausberg
Aug 18, 2009·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Arthur J PopeArturo J Cardounel
Nov 12, 2009·Journal of Cardiovascular Pharmacology and Therapeutics·Yan WangNiuLiang Cheng
Feb 27, 2010·Journal of Molecular and Cellular Cardiology·An L MoensLili A Barouch
Jan 22, 2011·Journal of the American Society of Hypertension : JASH·Ramprasad KandavarThomas D Giles
Mar 29, 2012·Vascular Health and Risk Management·Jorge Eduardo ToblliFernando Pablo Dominici
Jun 8, 2012·American Journal of Physiology. Renal Physiology·Ming-Guo FengL Gabriel Navar
Mar 9, 2013·Current Topics in Medicinal Chemistry·Georgios BourasChristodoulos Stefanadis
Nov 14, 2013·Frontiers in Physiology·Valeria ContiAmelia Filippelli
Apr 23, 2014·The Canadian Journal of Cardiology·Jonathan G Howlett
Dec 3, 2014·Clinica Chimica Acta; International Journal of Clinical Chemistry·Patrícia Nessralla AlpoimLuci Maria SantAna Dusse

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Related Papers

Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
Guo Wei-KangLiu Wen-Hu
Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
Jin-cheng LiDe-ming Tan
© 2021 Meta ULC. All rights reserved